Olema Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 11, 2024
OLMA$7.27-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(Amounts in thousands, except for share and per share amounts)
| Years Ended December 31, | ||||
|---|---|---|---|---|
| 2023 · 2022 | ||||
| Operating expenses: | ||||
| Research and development | $ | 86,140 | $ | 82,274 |
| General and administrative | 18,821 | 24,714 | ||
| Total operating expenses | 104,961 | 106,988 | ||
| Loss from operations | (104,961) | (106,988) | ||
| Other income (expense): | ||||
| Interest income | 8,325 | 2,228 | ||
| Other expense | (19) | (27) | ||
| Total other income | 8,306 | 2,201 | ||
| Net loss | $ | (96,655) | $ | (104,787) |
| Net loss per share, basic and diluted | $ | (2.14) | $ | (2.62) |
| Weighted average shares used to compute net loss per share, basic and diluted | 45,247,098 | 39,995,460 | ||
| Years Ended December 31, | ||||
|---|---|---|---|---|
| 2023 · 2022 | ||||
| Net loss | $ | (96,655) | $ | (104,787) |
| Other comprehensive loss: | ||||
| Net unrealized gain (loss) on marketable securities | 2,160 | (1,664) | ||
| Total comprehensive loss | $ | (94,495) | $ | (106,451) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.